CLINICAL STUDIES ON AC-1370
スポンサーリンク
概要
- 論文の詳細を見る
AC-1370, a new parenteral cephalosporin, was evaluated clinically for 12 patients (15 cases) aged 36-77 years with respiratory tract infection (4 cases) and with urinary tract infection (11 cases). A daily dose of AC-1370 was 1-2 g by intravenous injection twice a day and duration of AC-1370 therapy was for 5 to 9 days.<BR>The results were as follows.<BR>1. The clinical response to AC-1370 therapy of respiratory tract infection was good in 2 cases, fair in one case, and poor in one case, and that of urinary tract infection was excellent in 2 cases, good in 4 cases, and fair in 2 cases.<BR>The efficacy rate was 67%.<BR>2. In the laboratory data, abnormal elevation of serum Al-P, as a side effect, was observed in one case after the administration of AC-1370.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.